As your in silico partner

Basecamp Research supercharges your R&D

Access global biodiversity

Discover new enzymes, transcription factors, transporters, and chaperones

Explore novel regulatory elements: promoters, enhancers, ribosomal binding sites, and terminators

Learn from full-length metabolic pathways and gene arrays

Accelerate lab testing

Overcome throughput challenges with our graph-based sequence selection

Prioritise proteins optimal for your process conditions

Identify enzymes with altered or novel substrate specificity

Adhere to regulation

Achieve freedom-to-operate (FTO) with our highly divergent sequences

Align with the Nagoya Protocol with our fully compliant sequences

Match homologous genes from related taxonomies to your strain

FTSE100 pharma manufacturer

Our partner struggled to manufacture a desired chemical at scale, via either conventional or enzymatic methods. They exhausted all known enzyme sequences after >5 rounds of engineering.

In one week, we identified a successful enzyme that would have never been tested otherwise (ranked #760 with conventional prioritisation).

Venture-backed biotech

Our partner had far too many candidates to physically screen. Existing methods of protein function prediction could not discriminate the desired substrate specificity from the generic protein class.

We eliminated 99.8% of the broad candidate pool within 4 weeks, selecting 30 proteins with the best functional match to be tested.

Global top 5 nutrition company

Our partner needed a step-change in protein performance to increase their market share. There's only four known proteins from nature in existence. Regular computational or AI companies can only evolve from these existing four.

Our knowledge graph predicted entirely novel proteins with superior performance, allowing our customer to resume this product line optimisation.

Rooted in Access and Benefit Sharing

Future-proofed data collection

At the heart of our biodiscovery process is a our commitment to Access and Benefit Sharing (ABS). ABS is a cornerstone principle of the Convention on Biological Diversity and its Nagoya Protocol, which seeks to ensure fair and equitable sharing of benefits arising from the utilisation of genetic resources.

We're building a robust model for long term biodiversity protection through our global sampling partnerships. Each of our samples is collected in compliance with the Nagoya Protocol and with pre-negotiated permission to commercialise with our industry partners. Our aim is to create a world where industrial innovation protects, supports and revitalises our natural biodiversity.

Partner with us

See how we can help with your target enzymes and applications

We partner with people all across the bioeconomy, including agritech, food, API manufacture, cosmetics and more.
‍
So whether you're a synthetic biologist developing living therapeutics, a metabolic engineer enhancing biofuel production, or an enzymologist designing biocatalysts for bioplastics, give us a shout!

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Our news

The latest from Basecamp Research

Basecamp Research Launches BaseFold: A Breakthrough in 3D Protein Structure Prediction of Large, Complex Protein Structures

BaseFold leverages Basecamp Research's purpose-built foundational dataset to significantly increase prediction accuracy of large, complex protein structures and small molecule interactions — it is up to six times more accurate than AlphaFold2 and offers up to a three-fold improvement in small molecule docking.

Improving AlphaFold2 Performance with a Global Metagenomic & Biological Data Supply Chain

With higher protein sequence diversity captured in this dataset compared to existing public data, we apply this data advantage to the protein folding problem by MSA supplementation during inference of AlphaFold2.

Why we’re so excited about the Arc Institute’s new Evo model

At Basecamp Research, we’re on a mission to build the perfect foundational datasets for AI in biology. Now, finally, it feels like the model architectures are beginning to get sophisticated enough to unlock the true potential of what we’ve built.

Partner with us to make our proteins, your proteins